• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

ABCD Study Results: Is There a Link Between Prenatal Cannabis Use and Adverse Psychopathological Effects in Children?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Prenatal cannabis use has increased by approximately 100% from 2002 to 2017
    • Few studies have investigated possible associations between maternal cannabis use in pregnancy and adverse neonatal outcomes
  • Paul et al. (JAMA Psychiatry, 2020) assessed whether cannabis use during pregnancy is associated with adverse outcomes among offspring

METHODS:

  • Cross-sectional study
  • Data source
    • Ongoing longitudinal Adolescent Brain and Cognitive Development (ABCD) Study
  • Participants
    • Children aged 9 to 11
    • Their parents/caregivers from 22 sites across the U.S.
  • Exposure
    • Prenatal cannabis exposure prior to maternal knowledge of pregnancy
    • Cannabis exposure after maternal knowledge of pregnancy
  • Study design
    • Psychopathology in children definition: Psychotic-like experiences (PLEs) and/or internalizing, externalizing, attention, thought, and social problems
    • Covariates included
      • Familial (e.g. income and familial psychopathology)
      • Pregnancy-related (e.g. prenatal exposure to alcohol and tobacco)
      • Child (e.g. substance use)
  • Primary outcome
    • Symptoms of psychopathology in children
    • Cognition
    • Sleep
    • Birth weight
    • Gestational age at birth
    • BMI
    • Brain structure (total intracranial volume, white matter volume, and gray matter volume)

RESULTS:

  • 11,489 children included
    • 52.2% boys
    • Mean (SD) age: 9.9 (0.6) years
  • Prenatal cannabis exposure: 5.7% (655 children)
  • Compared to no exposure, cannabis exposure both before and after maternal knowledge of pregnancy was associated with
    • Greater offspring psychopathology characteristics
    • More sleep problems
    • Higher BMI
    • Lower cognition
    • Lower grey matter volume (P<0.03)
  • Compared to both no exposure and exposure only before maternal knowledge of pregnancy, exposure after maternal knowledge of pregnancy was associated with
    • Lower birth weight
    • Lower total intracranial volume
    • Lower white matter volume (P<0.04)
    • When potential confounding covariates were included, exposure after maternal knowledge of pregnancy was still associated with greater PLEs and externalizing, attention, thought, and social problems (P<0.04)
  • When considering potential confounding variables, there were no significant differences in any outcomes between exposure only prior to maternal knowledge of pregnancy and no exposure (P>0.70)

CONCLUSION:

  • Prenatal cannabis use is associated with a greater risk for psychopathology during middle childhood
    • This increased risk does not exist when maternal cannabis use was restricted to the time prior to maternal knowledge of pregnancy
  • The authors conclude that

…associations were robust to the inclusion of potentially confounding variables increases the plausibility that prenatal cannabis exposure may be independently associated with psychopathology risk in children

In contrast to increasingly permissive attitudes surrounding cannabis use among pregnant mothers and suggestions by dispensaries to use cannabis to combat pregnancy-related nausea, our findings align with recent recommendations by the US Surgeon General regarding the potential association of in utero cannabis exposure with outcomes in children

Learn More – Primary Sources:

Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Cannabis Use During Pregnancy Increase Risk of Preterm Birth?
ACOG Recommendations on Marijuana Use During Pregnancy and Lactation
Does Daily Marijuana Use in Pregnancy Impair Fetal Growth?
Does Socioeconomic Status Affect Risk of Adverse Birth Outcomes?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site